RELAY THERAPEUTICS INC

Relay Therapeutics’ stock lags behind peers amid low volume and a muted 2026 outlook, urging investors to watch pipeline updates for a potential turnaround.

Relay Therapeutics jumps 7.96% as biotech investors chase a fragile surge—why the rally may be more hype than solid value.

Relay Therapeutics surges nearly 5% as its oncology pipeline gains traction, boosting a $3.6B market cap and sparking investor confidence.